Skip to main content
L

Not yet reviewed: this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

Cinolazepam

This article is a stubmissing:
Subjective Effects
Interactions
Tolerance
Legality
Cinolazepam molecule structureCinolazepam molecule structure
Open in Piru
Chemical Class
1,4-Benzodiazepine

Cinolazepam is a 1,4-benzodiazepine derivative and depressant with anxiolytic, sedative, anticonvulsant, and skeletal muscle relaxant properties. Oral cinolazepam at 40 mg significantly improved sleep maintenance compared with placebo in a double-blind sleep-laboratory study of 20 young normal subjects whose sleep was disturbed by traffic noise1, with milder euphoria than some other benzodiazepines. It was patented in 1978 and entered medical use in 1992. The drug is described as habit-forming.2

Dosage & Duration

Log in Piru

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~10 mg
Light10-30 mg
Moderate30-60 mg
Strong60-120 mg
Heavy120+ mg

Duration

Onset30-90 minutes
After Effects12-20 hours
Total8-12 hours

Subjective Effects

Subjective Effects not written up yet

Pharmacology

Pharmacodynamics

Cinolazepam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative, and skeletal muscle relaxant properties.3 Its sedative effects are particularly strong, and it is primarily used as a hypnotic.

Pharmacokinetics

Absorption & half-lifenot documented yetMetabolitesnone documented yet

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check TripSit

Tolerance

Tolerance not written up yet

Harm Potential

Addiction & Dependence

Psychological

Moderate

As a benzodiazepine, cinolazepam carries moderate potential for psychological dependence with regular use.

Physical

High

Benzodiazepines as a class produce significant physical dependence with regular use, and withdrawal can be severe and potentially life-threatening.

History & Culture

Cinolazepam was patented in 1978 and entered medical use in 1992. It was listed among nationally authorised medicinal products under the name Gerodorm4 and was used mainly in Romania and Slovakia.

Legality

Legality not written up yet

References

Citations

  1. Short-term sleep laboratory studies with cinolazepam in situational insomnia induced by traffic noise. PubMed (1987). https://pubmed.ncbi.nlm.nih.gov/28896791
  2. Gerodorm 40 mg comprimate: Prospect. ANMDMR (2025). https://www.anm.ro/_/_PRO/PRO_6228_07.03.14.pdf1
  3. Cinolazepam: Uses, Interactions, Mechanism of Action. DrugBank (n.d.). https://go.drugbank.com/drugs/DB015941
  4. cinolazepam: List of nationally authorised medicinal products. European Medicines Agency (2020). https://www.ema.europa.eu/en/documents/psusa/cinolazepam-list-nationally-authorised-medicinal-products-psusa00000769201912_en.pdf1

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed: this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the Cinolazepam article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.